Skip to main content
. Author manuscript; available in PMC: 2011 Jan 6.
Published in final edited form as: Mol Cancer Ther. 2010 Jan 6;9(1):190–201. doi: 10.1158/1535-7163.MCT-09-0694

Figure 3.

Figure 3

PA-L1/LF efficacy in orthotopic BHT-101 and DRO xenografts. Mice bearing 5-day old BHT-101 or DRO orthotopic tumors were treated with either 30 μg PA-L1/10 μg LF in 500 μl PBS or PBS alone 3 times a week for 2 weeks. At day 21, mice were euthanized and tumor volume was determined. Error bars represent SEM. (A) PBS-treated BHT-101 and DRO tumors averaged 285 and 200 mm3 while PA-L1/LF-treated tumors were 3.7 and 4 mm3, respectively. (B) Representative mice from each tumor type and treatment group are shown. Tumors are indicated by white arrows. *unpaired t test p value <.05.